Fragile dopamine
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
FMR1 has been suggested as important for DA signaling in both the prefrontal cortex and striatum, where it may interact with G protein-coupled receptor kinase 2, which regulates DA receptor signaling cascades.
“FMR1 has been suggested as important for DA signaling in both the prefrontal cortex and striatum, where it may interact with G protein–coupled receptor kinase 2, which regulates DA receptor signaling cascades [714].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [714]
There is evidence that DA functioning may be atypical in FXS, as shown by high rates of comorbidity with tremor disorders, higher blink rates, and emerging preclinical models.
“However, there is evidence that DA functioning may be atypical in FXS, as shown by high rates of comorbidity with tremor disorders [725], higher blink rates [726], and emerging preclinical models [714].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [714]
Cites
The debate over dopamine’s role in reward: the case for incentive salience
Berridge, K. C. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0578-x · Cited by 2,347 · see citing works
Dopamine-mediated regulation of corticostriatal synaptic plasticity
Calabresi, P., Picconi, B., Tozzi, A., & Di Filippo, M. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.001 · Cited by 865 · see citing works
Garber, K. B., Visootsak, J., & Warren, S. T. (2008) · European Journal of Human Genetics · doi:10.1038/ejhg.2008.61 · Cited by 477 · see citing works
Self-citationThe Pathophysiology of Fragile X Syndrome
Penagarikano, O., Mulle, J. G., & Warren, S. T. (2007) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.8.080706.092249 · Cited by 420 · see citing works
Self-citationDopaminergic Mechanisms in Actions and Habits: Figure 1.
Wickens, J. R., Horvitz, J. C., Costa, R. M., & Killcross, S. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.1671-07.2007 · Cited by 271 · see citing works
Brennan, A. R., & Arnsten, A. F. T. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1417.007 · Cited by 267 · see citing works
FMRP Acts as a Key Messenger for Dopamine Modulation in the Forebrain
Wang, H., Wu, L.-J., Kim, S. S., Lee, F. J. S., Gong, B., Toyoda, H., Ren, M., Shang, Y.-Z., Xu, H., Liu, F., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.027 · Cited by 186 · see citing works
Problem behavior in boys with fragile X syndrome
Hatton, D. D., Hooper, S. R., Bailey, D. B., Skinner, M. L., Sullivan, K. M., & Wheeler, A. (2002) · American Journal of Medical Genetics · doi:10.1002/ajmg.10216 · Cited by 149 · see citing works
Hooper, S. R., Hatton, D. D., Sideris, J. H., Sullivan, K. M., Hammer, J., Schaaf, J. M., Mirrett, P., Ornstein, P. A., & Bailey, D. B. (2008) · Neuropsychology · doi:10.1037/0894-4105.22.1.36 · Cited by 117 · see citing works
Cyclic AMP metabolism in fragile X syndrome
Berry‐Kravis, E., & Huttenlocher, P. R. (1992) · Annals of Neurology · doi:10.1002/ana.410310105 · Cited by 81 · see citing works
The cyclic AMP phenotype of fragile X and autism
Kelley, D. J., Bhattacharyya, A., Lahvis, G. P., YIN, J., Malter, J. S., & Davidson, R. J. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.06.005 · Cited by 56 · see citing works
Reducing glutamate signaling pays off in fragile X
Bassell, G. J., & Groß, C. (2008) · Nature Medicine · doi:10.1038/nm0308-249 · Cited by 24 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Fragile X Syndrome: Loss of Local mRNA Regulation Alters Synaptic Development and Function
Bassell, G. J., & Warren, S. T. (2008) · Neuron · doi:10.1016/j.neuron.2008.10.004 · Cited by 1,051 · see citing works
Self-citationMolecular Mechanisms of Fragile X Syndrome: A Twenty-Year Perspective
Santoro, M. R., Bray, S. M., & Warren, S. T. (2012) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132457 · Cited by 528 · see citing works
Self-citationDichter, G. S., Damiano, C. A., & Allen, J. A. (2012) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-4-19 · Cited by 299 · see citing works
Gross, C., Nakamoto, M., Yao, X., Chan, C.-B., Yim, S. Y., Ye, K., Warren, S. T., & Bassell, G. J. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0402-10.2010 · Cited by 241 · see citing works
Self-citationSaab, B. J., Georgiou, J., Nath, A., Lee, F. J. S., Wang, M., Michalon, A., Liu, F., Mansuy, I. M., & Roder, J. (2009) · Neuron · doi:10.1016/j.neuron.2009.08.014 · Cited by 198 · see citing works
Long-term potentiation in the anterior cingulate cortex and chronic pain
Zhuo, M. (2013) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2013.0146 · Cited by 198 · see citing works
Wu, J., Meng, Z., Xu, J., Lei, Y., Lin, J., Zhong, P., Han, R., & Su, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054322 · Cited by 66 · see citing works
Wang, H., Kim, S. S., & Zhuo, M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.116293 · Cited by 52 · see citing works
Kenkel, W. M., Yee, J. R., Moore, K., Madularu, D., Kulkarni, P., Gamber, K., Nedelman, M., & Ferris, C. F. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.15 · Cited by 39 · see citing works
Genetic and Epidemiologic Characterization of HIV-1 Infection In Liaoning Province, China
Han, X., Dai, D., Zhao, B., Liu, J., Ding, H., Zhang, M., Hu, Q., Lu, C., Goldin, M., Takebe, Y., et al. (2010) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181c7d5bf · Cited by 34 · see citing works
β-N-Methylamino-L-alanine (BMAA) Toxicity Is Gender and Exposure-Age Dependent in Rats
Scott, L. L., & Downing, T. G. (2017) · Toxins · doi:10.3390/toxins10010016 · Cited by 33 · see citing works
Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes
Wang, H., Pati, S. B. B., Pozzo‐Miller, L. D., & Doering, L. C. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00055 · Cited by 25 · see citing works
Xu, J., Wang, S., Chen, Y., Chen, G.-P., Li, Z., Shao, X., Li, L., Lu, W., & Zhou, T. (2014) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.19 · Cited by 12 · see citing works
The inhibition of NCS-1 binding to Ric8a rescues fragile X syndrome mice model phenotypes
Cogram, P., Fernández-Beltrán, L. C., Casarejos, M. J., Sánchez-Yepes, S., Rodríguez‐Martín, E., García‐Rubia, A., Sánchez-Barrena, M. J., Gil, C., Martı́nez, A., & Mansilla, A. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.1007531 · Cited by 5 · see citing works
Potential pharmacological treatment of fragile X syndrome during adulthood
Xu, Z., & Zhao, M. (2009) · Neuroscience Bulletin · doi:10.1007/s12264-009-0909-0
- Authors
- Weinshenker, D., & Warren, S. T.
- Affiliations
- Emory University (US)
- Venue
- Nature
- Published
- 2008-10
- Volume
- 455
- Issue
- 7213
- Pages
- 607-608
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2070236445
- Cited by
- 15
- References
- 12
- Citations by year
- 2022: 1 · 2017: 1 · 2016: 1 · 2015: 1 · 2014: 1 · 2013: 2 · 2012: 1
- FWCI
- 1.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- fragile X syndrome, dopamine, dopaminergic dysfunction, Parkinson's disease, drug addiction, FMRP, neurodegeneration
- MeSH terms
- Animals, Dopamine, Fragile X Syndrome, Humans, Signal Transduction, Gene Deletion, Mice, Fragile X Messenger Ribonucleoprotein 1, Fragile X Mental Retardation Protein, G-Protein-Coupled Receptor Kinase 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review